Microwave ablation combined with immune checkpoint inhibitor enhanced the antitumor immune activation and memory in rechallenged tumor mouse model DOI Creative Commons
Fengkuo Xu,

Jing Sang,

Nan Wang

et al.

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(5)

Published: March 25, 2025

Microwave ablation (MWA) is a super minimally invasive therapeutic approach that has been widely applied in the treatment of non-small cell lung cancer (NSCLC). Although MWA can elicit antitumor immune responses, these responses are not relatively steady and insufficient to completely clear recurrence tumor cells within body. Immunotherapy monotherapy shown low clinical efficacy advanced NSCLC. combined with checkpoint inhibitors (ICIs) promising approach. However, mechanism synergic effect remains elusive. In this study, we have conducted retrospective analysis outcomes ICIs, finding combinational therapy yielded superior Objective Response Rate longer Progression-Free Survival. preclinical models, established rechallenged model address post-MWA delve into underlying mechanisms therapy. We observed (MWA + PD-L1 blockade therapy) effectively addressed issue model. The increased function percentage CD8+ tumor-infiltrating lymphocytes, enhanced functionality T tumor-draining lymph nodes (TdLNs), elevated proportion central memory cells. Additionally, treatments promoted Migration Dendritic Cells type 1 (Mig DC1) TdLNs, thereby enhancing their activation potential. Notably, FTY720-mediated lymphocyte egress abolished benefits, confirming TdLNs-dependent systemic immunity. Moreover, depended on migration from TdLNs site. summary, proposed potentially effective regimen elucidated cellular underpin its efficacy.

Language: Английский

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions DOI
Yibei Wang, Mohammed Safi, Fred R. Hirsch

et al.

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: 22(3), P. 200 - 214

Published: Jan. 6, 2025

Language: Английский

Citations

1
Peptide-functionalized gold nanostars-assisted single-cell Raman spectra for molecular analysis of tumor metastasis based on cancer stem cells DOI

Zhiyi Peng,

Han Yao, Junqi Li

et al.

Talanta, Journal Year: 2025, Volume and Issue: 286, P. 127525 - 127525

Published: Jan. 7, 2025

Language: Английский

Citations

1
N-acetyltransferase 10 impedes EZH2/H3K27me3/GABARAP axis mediated autophagy and facilitates lung cancer tumorigenesis through enhancing SGK2 mRNA acetylation DOI
Nan Xiao, Hongyang Liu, Ruike Zhang

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 139823 - 139823

Published: Jan. 1, 2025

Language: Английский

Citations

1
Thoracic Malignancies: From Prevention and Diagnosis to Late Stages DOI Creative Commons
Julien Ancel, Laura Bergantini, Paolo Mendogni

et al.

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 138 - 138

Published: Jan. 21, 2025

Lung cancer remains the leading cause of cancer-related mortality worldwide, characterized by its complexity and heterogeneity [...]

Language: Английский

Citations

1
CircKIAA0182 Enhances Lung Cancer Progression and Chemoresistance through Interaction with YBX1 DOI
Masha Huang,

Jingyi Sun,

Qingqing Jiang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: 612, P. 217494 - 217494

Published: Jan. 23, 2025

Language: Английский

Citations

1
Traditional Chinese medicine in lung cancer treatment DOI Creative Commons
Zhichao Xi,

Rongchen Dai,

Yufei Ze

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 26, 2025

Lung cancer remains a major global health challenge and one of the leading causes cancer-related deaths worldwide. Despite significant advancements in treatment, challenges such as drug resistance, side effects, metastasis recurrence continue to impact patient outcomes quality life. In response, there is growing interest complementary integrative approaches care. Traditional Chinese medicine (TCM), with its long history, abundant clinical experience, holistic perspective individualized approach, has garnered increasing attention for role lung prevention management. This review provides comprehensive overview advances TCM covering theoretical foundation, treatment principles, experiences evidence supporting efficacy. We also provide systematic summary preclinical mechanisms, through which impacts cancer, including induction cell death, reversal inhibition modulation immune responses. Additionally, future prospects are discussed, offering insights into expanded application integration modern address this challenging disease.

Language: Английский

Citations

1
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies DOI Open Access
Nicolas Roussot,

Courèche Kaderbhaï,

François Ghiringhelli

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 906 - 906

Published: March 6, 2025

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy targeting the PD-1/PD-L1 axis has revolutionized treatment, providing durable responses in subset patients. However, with fewer than 50% patients achieving significant benefits, there is critical need to expand therapeutic strategies. This review explores emerging targets immune checkpoint inhibition beyond PD-1/PD-L1, including CTLA-4, TIGIT, LAG-3, TIM-3, NKG2A, and CD39/CD73. We highlight biological basis CD8 T cell exhaustion shaping antitumor response. Novel approaches additional inhibitory receptors (IR) are discussed, focus on their distinct mechanisms action combinatory potential existing therapies. Despite advancements, challenges remain overcoming resistance optimizing patient selection. underscores importance dual blockade innovative bispecific antibody engineering maximize outcomes for NSCLC

Language: Английский

Citations

1
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action DOI
May-Lucie Meyer,

S. Peters,

Tony Mok

et al.

Annals of Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

6
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence? DOI
Jordi Remón,

Martina Bortolot,

Paolo Bironzo

et al.

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens been considered standard care, with ICBs administered at flat doses regardless patients’ weight. Treatment duration is often arbitrary across stages, ranging from a fixed time point to until disease progression or unacceptable toxicity. However, pharmacokinetic and pharmacodynamic properties differ significantly those traditional cytotoxic drugs approved selected on basis maximum tolerated dose are overestimated as there limited evidence supporting direct relationship between therapeutic intensity outcomes. This can lead overtreatment patients, resulting in an increased risk toxicity without enhanced efficacy. In addition, use these associated significant costs that burden global health care system exacerbate disparities access care. De-escalating by reducing dose, duration, frequency administration could optimize efficacy, reduce toxicities, improve patients' quality life, even decrease costs. Ultimately, de-escalation strategies may help inequalities drug worldwide. The aim this review summarize discuss main issues challenges regarding patients NSCLC, focusing dose-intensity reduction selection. Moreover, we assess economic impact implementing approaches.

Language: Английский

Citations

0
A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice DOI Creative Commons
Agnieszka Stawarska, Magdalena Bamburowicz‐Klimkowska, Dariusz Maciej Pisklak

et al.

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 202 - 202

Published: Jan. 29, 2025

Metabolomics is a powerful tool that can be used to identify different stages in cancer development. In this study, the metabolomic profile of Lewis lung carcinoma (LLC) was characterized C57BL/6 mice bearing LLC tumors. Magnetic resonance spectroscopy (nuclear magnetic resonance—NMR) applied using 400 MHz 1H NMR spectrometer. Two types metabolites (polar and non-polar) were identified on based analysis methanol/water chloroform extracts collected from samples mice. The investigated metabolomics show neoplastic processes growing may affect carbohydrate; alanine glutamate; leucine isoleucine; lysine; creatine; choline metabolism, whereas hypoxia states due elevated lactate tissues. could considered valuable biomarker translational research.

Language: Английский

Citations

0